By Fineline Cube Regent Pacific Group Limited (HKG: 0575) announced that the New Drug Application (NDA) for its innovative therapy Senstend has been approved by China’s National Medical Products Administration (NMPA), accompanied by a four-year data protection period. The metered-dose aerosol, developed by Plethora Solutions and indicated for premature ejaculation, triggered an immediate USD 5 million milestone payment from commercialization partner Jiangsu Wanbang Pharmaceutical Technology Co., Ltd.
Regulatory & Commercial Milestone
| Item | Detail |
|---|---|
| Company | Regent Pacific Group Limited (HKG: 0575) |
| Product | Senstend – metered-dose aerosol for premature ejaculation |
| Regulatory Authority | National Medical Products Administration (NMPA), China |
| Approval Type | New Drug Application (NDA) approval |
| Data Protection | Four-year exclusivity period |
| Acquisition History | Plethora Solutions acquired by Regent Pacific in 2016 |
| Commercial Partner | Jiangsu Wanbang Pharmaceutical Technology Co., Ltd (exclusive license since 2018) |
Product Profile & Therapeutic Innovation
- Formulation: Proprietary blend of lidocaine and prilocaine in metered-dose aerosol delivery system
- Indication: Treatment of premature ejaculation – addressing significant unmet need in men’s sexual health
- Delivery Advantages: Topical aerosol formulation enables rapid onset, precise dosing, and improved patient compliance compared to oral alternatives
- Clinical Differentiation: Local anesthetic combination provides targeted efficacy with minimal systemic exposure
- Market Position: First-in-class topical aerosol therapy for premature ejaculation in Chinese market
Financial Impact & Milestone Structure
Immediate Financial Benefits
- First Milestone: USD 5 million payment triggered upon NMPA approval (received)
- Second Milestone: Additional USD 2 million payment expected upon commercial launch in H2 2026
- Total Near-Term Value: USD 7 million in milestone payments within 6-12 months
Commercial Launch Timeline
- Expected Launch: Second half of 2026 by Jiangsu Wanbang
- Market Entry: First mover advantage in premium men’s sexual health segment
- Revenue Potential: Significant addressable market given high prevalence of premature ejaculation in China
- Pricing Strategy: Premium positioning supported by innovative delivery system and data protection exclusivity
Market Impact & Strategic Implications
- Men’s Health Market: Addresses substantial unmet need in China’s underserved men’s sexual health segment
- Data Protection Value: Four-year exclusivity provides significant competitive moat against potential generics
- Partnership Model Success: Validates Regent Pacific’s acquisition and out-licensing strategy for China market entry
- Regulatory Achievement: NDA approval demonstrates successful navigation of China’s stringent regulatory requirements for novel formulations
- Global Potential: China approval may support regulatory filings in other Asian markets
Strategic Outlook
The NMPA approval of Senstend represents a significant validation of Regent Pacific’s strategic acquisition of Plethora Solutions and its partnership approach to China market entry. The four-year data protection period provides substantial commercial runway for market penetration and revenue generation, while the milestone payment structure delivers immediate financial benefits with limited capital investment. This success positions Regent Pacific to potentially explore additional indications or geographic expansions for its proprietary topical delivery platform, building on the foundation established through the Senstend approval.
Forward‑Looking Statements
This brief contains forward-looking statements regarding commercial launch timing, milestone payments, and market performance. Actual results may differ due to commercial execution, market adoption, competitive dynamics, and regulatory compliance requirements.-Fineline Info & Tech